Cryo-Cell International Inc 2024年度报告

☒ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.For the fiscal year endedNovember 30,2024☐TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.For the transition period fromtoCommission File Number001-40767CRYO-CELL INTERNATIONAL, INC . (Exact Name of registrant as specified in its charter) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☑ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YesoNo☑ Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☑No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-Tduring the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growthcompany. See definition of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.(Check one): Large accelerated filer☐Accelerated filerNon-accelerated filer☒Smaller reporting companyEmerging growth companyo(Do not check if a smaller reporting company) If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect thecorrection of an error to previously issued financial statements.o Indicate by check mark whether any of the error corrections are restatements that required a recovery analysis of incentive-based compensation received by any registrant's executive officers during the relevant recovery period pursuant to 240.10D-1(b).o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). YesoNo☑ The aggregate market value of the Registrant’s Common Stock held by non-affiliates of the Registrant is computed by reference to the price at which the common stockwas last sold as of the last business day of the Registrant’s most recently completed second fiscal quarter (May 31, 2024) was $43,849,869.As of February 28, 2025, there were8,082,159shares of Common Stock outstanding. None. Auditor Firm Id:344 Auditor Location:Atlanta, TABLE OF CONTENTS PagePART IFORWARD-LOOKING STATEMENTS1ITEM 1.BUSINESS1ITEM 1A.RISK FACTORS11ITEM 1B.UNRESOLVED STAFF COMMENTS25ITEM 1C.CYBERSECURITY25ITEM 2.PROPERTIES26ITEM 3.LEGAL PROCEEDINGS27ITEM 4.MINE SAFETY DISCLOSURES27PART IIITEM 5.MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERSAND ISSUER PURCHASES OF EQUITY SECURITIES28ITEM 6.SELECTED FINANCIAL DATA28ITEM 7.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTSOF OPERATIONS29ITEM 7A.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK40ITEM 8.FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA41ITEM 9.CHANGESIN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING ANDFINANCIAL DISCLOSURE76ITEM 9A.CONTROLS AND PROCEDURES76ITEM 9B.OTHER INFORMATION77PART IIIITEM 10.DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE78ITEM 11.EXECUTIVE COMPENSATION80ITEM 12.SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT ANDRELATED STOCKHOLDER MATTERS85ITEM 13.CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTORINDEPENDENCE86ITEM 14.PRINCIPAL ACCOUNTANT FEES AND SERVICES86PART IVITEM 15.EXHIBITS AND FINANCIAL STATEMENT SCHEDULES88ITEM 16.FORM 10-K SUMMARY90SIGNATURES91 Forward-Looking Statements This Form 10‑K, press releases and certain information provided periodically in writing or orally by the Company'sofficers or its agents may contain statements which constitute "forward‑looking statements".The terms "Cryo-Cell International,Inc.," “Cryo-Cell,” "Company," "we," "our" and "us" refer to Cryo-Cell International, Inc. The words "expect," "believe," "goal,""plan,""intend,""estimate"and similar expressions and variations thereof,if used,are intended to specifically identifyforward‑looking sta